BioMarin Pharmaceutical (GB:0HNC)

BioMarin Pharmaceutical Financial Statements


BioMarin Pharmaceutical Financial Overview

BioMarin Pharmaceutical's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; BioMarin Pharmaceutical is scheduled to report earnings on October 26, 2022, and the estimated EPS forecast is
lt;0.01. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Mar 22Dec 21Sep 21Jun 21
Income Statement
Total Revenue$ 533.80M$ 519.36M$ 449.81M$ 408.74M$ 501.69M
Gross Profit$ 410.67M$ 402.39M$ 330.06M$ 305.20M$ 374.63M
EBIT$ 38.71M$ 137.99M$ -63.32M$ -42.29M$ 17.82M
EBITDA$ 63.98M$ 165.34M$ -37.34M$ -15.45M$ 45.06M
Net Income Common Stockholders$ 27.66M$ 120.80M$ -57.90M$ -36.49M$ 12.94M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 1.01B$ 1.06B$ 1.07B$ 1.08B$ 1.09B
Total Assets$ 6.15B$ 6.06B$ 6.00B$ 5.98B$ 5.90B
Total Debt$ 1.08B$ 1.09B$ 1.09B$ 1.09B$ 1.09B
Net Debt$ 69.95M$ 29.37M$ 21.35M$ 8.46M$ 1.63M
Total Liabilities$ 1.64B$ 1.67B$ 1.73B$ 1.71B$ 1.66B
Stockholders Equity$ 4.05B$ 4.11B$ 4.16B$ 4.24B$ 4.27B
Cash Flow
Free Cash Flow$ 28.19M$ -76.11M$ -33.18M$ 76.70M$ 56.53M
Operating Cash Flow$ 56.23M$ -45.43M$ 11.18M$ 97.06M$ 82.78M
Investing Cash Flow$ -29.70M$ 87.78M$ -55.42M$ -119.85M$ -120.26M
Financing Cash Flow$ -11.78M$ -25.28M$ 14.40M$ -1.03M$ 10.95M
Currency in USD

BioMarin Pharmaceutical Earnings and Revenue History

BioMarin Pharmaceutical Debt to Assets

BioMarin Pharmaceutical Cash Flow

BioMarin Pharmaceutical Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis